ArticleCancer chemotherapy and pharmacology2022

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.

Nusayba A Bagegni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.